Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Patients With ASD and Comorbid MDD Could Benefit From Transcranial Magnetic Stimulation

Key clinical point: Repetitive transcranial magnetic stimulation (rTMS) is effective and well tolerated in patients with autism and comorbid major depression.

Major finding: After rTMS treatment, a median decrease of 13.5 points was observed on the Hamilton rating scale for depression (HAM-D17) and 40% of patients achieved remission (HAM-D177). Side effects were mild and the treatment was well tolerated.

Study details: A prospective, open-label, single-arm study investigated the efficacy and safety of rTMS in 13 patients aged 18-65 years, diagnosed with comorbid autism spectrum disorder (ASD) and major depressive disorder (MDD).

Disclosures: The authors declared no conflicts of interest.


Gwynette MF et al. Autism Research. 2020 Jan 15. doi: 10.1002/aur.2266.